Peter Donhauser Biography and Net Worth

Director of Anavex Life Sciences

Dr. Peter Donhauser M.D. serves as Independent Director of the Company. He has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania. He has served as a director of the Company since February 8, 2017.

How do I contact Peter D.O. Donhauser?: The corporate mailing address for Dr. Donhauser and other Anavex Life Sciences executives is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. Anavex Life Sciences can also be reached via phone at (844) 689-3939 and via email at [email protected]. Learn More on Peter D.O. Donhauser's contact information.
Has Peter D.O. Donhauser been buying or selling shares of Anavex Life Sciences?: Peter D.O. Donhauser has not been actively trading shares of Anavex Life Sciences in the last ninety days. Learn More on Peter D.O. Donhauser's trading history.
Who are Anavex Life Sciences' active insiders?: Anavex Life Sciences' insider roster includes Sandra Boenisch (Treasurer), Peter Donhauser (Director), Elliot Favus (Director), and Elliot Favus (Director). Learn More on Anavex Life Sciences' active insiders.
Are insiders buying or selling shares of Anavex Life Sciences?: In the last twelve months, Anavex Life Sciences insiders bought shares 2 times. They purchased a total of 7,835 shares worth more than $32,919.40. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 73,380 shares worth more than $374,971.80. The most recent insider tranaction occured on June, 14th when Director Peter D.O. Donhauser bought 2,835 shares worth more than $10,319.40. Insiders at Anavex Life Sciences own 11.0% of the company. Learn More about insider trades at Anavex Life Sciences.
Information on this page was last updated on 6/14/2024.

Peter D.O. Donhauser Insider Trading History at Anavex Life Sciences

Peter D.O. Donhauser Buying and Selling Activity at Anavex Life Sciences

Anavex Life Sciences Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Today's Range

Now: $8.63

$8.26

$8.78

50 Day Range

MA: $7.69

$5.24

$9.46

2 Week Range

Now: $8.63

$3.25

$10.45

Volume

2,505,868 shs

Average Volume

1,218,407 shs

Market Capitalization

$731.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis

From Stansberry Research | Ad

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.